Evidence map›Paper›PMID 41372134›Full record

ArticleCell death & disease2025

De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.

Lirong Yan, Moye Chen, LuLu Cai, Aoran Liu, Fang Li, Yuzhe Zhang, Xiaoli Peng, Yan Wang, RuiPeng Li, Jipeng Mei and 5 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lirong Yan *The Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Moye Chen *Department of Gastroenterology, The First Hospital of China Medical University, Shenyang City, Liaoning Province, China.
LuLu CaiDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Aoran LiuThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Fang LiThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Yuzhe ZhangThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Xiaoli PengThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Yan WangThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
RuiPeng LiThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Jipeng MeiThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Dan ZouDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Xiaozhuo GaoDepartment of Pathology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Yiwei WangLiaoning Province Key Laboratory for Phenomics of Human Ethnic Specificity and Critical Illness, Shenyang, Liaoning, 110034, China. wangyiwei@symc.edu.cn.
Lina WuDepartment of Laboratory Medicine, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China. wuln@sj-hospital.org.
Ye ZhangThe Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China. zhangye83282356@163.com.ORCID http://orcid.org/0009-0008-5839-3413

Funding

National Natural Science Foundation of China (National Science Foundation of China) No.82203818National Natural Science Foundation of China (National Science Foundation of China) No.82573305
6 · The paper itself

Abstract

The enhanced adhesion between gastric cancer (GC) cells and peritoneal mesothelial cells (PMCs) is one of the key factors in the formation of the pre-peritoneal-metastasis adaptive microenvironment. USP35 belongs to the ubiquitin-specific protease family and is involved in regulating the occurrence and progression of various diseases. However, whether this gene can regulate the adhesion of GC cells to PMCs has not been clarified. The aim of this study was to identify the mechanism by which USP35 promotes the formation of the pre-peritoneal-metastasis adaptive microenvironment of GC and to find potential therapeutic targets. For the first time, we found that USP35 expression is upregulated in GC tissues, especially in peritoneal metastatic nodules, and is associated with poor prognosis. USP35 expression is the highest in MKN-45P, which is closely related to its high peritoneal metastasis potential. The mechanism of action involves several key steps. Firstly, the gene targets STING through de-ubiquitination and stabilizes its expression. Through this interaction, USP35/STING activates the HIF-1α/FAK pathway, promoting energy metabolism reprogramming and further improving the adhesion ability of GC cells. Secondly, exosome USP35 derived from GC cells has been shown to promote the mesothelial-mesenchymal transformation (MMT) of PMCs, preparing the "soil" for cancer cell adhesion and growth and contributing to the establishment of a pre-peritoneal-metastasis adaptive microenvironment. In summary, USP35 synergistically promotes the establishment of this environment through the dual mechanisms of regulating energy metabolic reprogramming of tumor cells and inducing the MMT of PMCs via the exosome pathway, providing a new theoretical basis for searching for therapeutic targets of gastric cancer with peritoneal dissemination.

Indexed as

Peritoneal NeoplasmsStomach NeoplasmsAnimalsCell AdhesionCell Line, TumorEpithelial-Mesenchymal TransitionExosomesFemaleGene Expression Regulation, NeoplasticHumansMaleMetabolic ReprogrammingMiceTumor Microenvironment

Identifiers

PMID41372134
PMCPMC12706015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.